We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Circulating Tumor Cell-Count Drives Therapy Choice for Breast Cancer

By LabMedica International staff writers
Posted on 18 Nov 2020
The choice between chemotherapy and endocrine therapy as first-line treatment for hormone receptor–positive, ERBB2 (also known as HER2)-negative metastatic breast cancer is usually based on the presence of clinical features associated with a poor prognosis.

Circulating Tumor Cell (CTC) test is a simple blood test that helps oncologists in assessing the prognosis of patients with metastatic breast, colorectal, or prostate cancer. More...
A prespecified circulating tumor cell count (CTC) threshold appeared to be reliable for selecting treatment with chemotherapy instead of hormone therapy in women with a certain metastatic breast cancer phenotype, a non-inferiority trial indicated.

A team of Medical Oncologists led by those at the Paris-Saclay University (Saint-Cloud, France) studied 755 women with hormone receptor-positive, ERBB2-negative metastatic breast cancer who were randomly assigned to receive first-line treatment based on CTC count or treatment based on clinician choice. In the CTC-count arm, women with CTC count of 5 CTCs/7.5 mL or greater were automatically assigned to chemotherapy instead of endocrine therapy. Data were collected at 17 French cancer centers from February 1, 2012, to July 28, 2016, and analyzed June 2019 to October 2019. The CELLSEARCH CTC System (Menarini Silicon Biosystems, Bologna, Italy) was used to capture and isolate tumor cells circulating in the blood in all patients.

The scientists reported that among the 755 women in the per-protocol population, the median (range) age was 63 (30-88) years: 64 (30-88) years for the 377 patients allocated to the CTC arm and 63 (31-87) years for the 378 patients allocated to the standard arm; 138 (37%) and 103 (27%) received chemotherapy, respectively. Median progression-free survival (PFS) was 15.5 months (95% CI, 12.7-17.3) in the CTC arm and 13.9 months (95% CI, 12.2-16.3) in the standard arm. The primary end point was met, with a hazard ratio of 0.94 (90% CI, 0.81-1.09).

In addition, more than one-third of patients had discordant CTC and clinical assessments. When these patients with clinical low risk and high CTC counts were pooled with clinical high risk/low CTC counts in a multivariable analysis, PFS and overall survival were higher for those treated with chemotherapy versus endocrine therapy. Overall survival in the per-protocol population was 47.3 months (95% CI 43.8-51.3) in the CTC arm and 42.8 months (95% CI 39.5-47.4) in the standard arm.

Francois-Clement Bidard, MD, PhD, Professor of Medical Oncology and senior author of the study, said, “The use of the CTC count represents the first objective and reproducible decision tool to help physicians choose between hormone therapy or chemotherapy for this particular group of patients.”

The authors concluded that this randomized clinical trial found that the CTC count may be a reliable biomarker method for guiding the choice between chemotherapy and endocrine therapy as the first-line treatment in hormone receptor–positive, ERBB2-negative metastatic breast cancer. The study was published on November 5, 2020 in the journal JAMA Oncology.

Related Links:
Paris-Saclay University
Menarini Silicon Biosystems



Gold Member
Serological Pipets
INTEGRA Serological Pipets
Portable Electronic Pipette
Mini 96
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.